AstraZeneca Shares Rise on Strong Cancer Treatment Sales
The pharmaceutical giant reported a 6% increase in first-half revenues, driven by demand for its oncology drugs.
Shares in AstraZeneca saw a significant increase following the company's announcement of boosted sales, primarily attributed to strong demand for its cancer treatments.
For the first half of the year, AstraZeneca reported a 6% rise in revenues, reaching £23 billion, with profits climbing 2% to £5 billion. Chief executive Pascal Soriot highlighted the robust performance of cancer medications, including Tagrisso and Imfinzi, as key drivers for this growth. The oncology division experienced a surge in sales, increasing by 15% to £10.6 billion, now constituting nearly half of the company's total sales.
AstraZeneca anticipates group annual sales to grow between 5% and 9% this year. Soriot emphasized the company's commitment to investing in transformative technologies and commercial strategies to deliver innovative medicines globally and sustain growth beyond 2030.
This positive financial update comes after recent setbacks for the company. Earlier in July, a trial for the potential blockbuster drug Wainua resulted in a significant drop in AstraZeneca's market value, erasing £23 billion in one day. In May, U.S. regulators also rejected a breast cancer drug developed by the company.
Despite these challenges, AstraZeneca shares climbed 1.7%, or 218 pence, to 12,888 pence on the day of the report. However, the stock remains down approximately 7% year-to-date. Soriot noted the imperative for AstraZeneca to operate with greater speed, akin to the pace seen in China's pharmaceutical industry, to maintain its competitive edge in innovation.